Back to companies

Biogen Inc: Overview

Want to continue viewing company data?

Sign up for exclusive competitive intelligence.
Company Data Subscription $329 per month (billed Annually)
Signup to View Free Sample

Biogen Inc (Biogen) is a biopharmaceutical company that discovers, develops, and delivers drugs and biosimilars for the treatment of various neurological and neurodegenerative diseases. The company’s marketed products include Avonex (interferon beta-1a), Tysabri (natalizumab), Tecfidera (dimethyl fumarate), Fampyra (prolonged-release fampridine tablets), and Plegridy (peginterferon beta-1a) for the treatment of multiple sclerosis (MS); Spinraza (nusinersen) for spinal muscular atrophy (SMA); and Fumaderm (fumaric acid esters) for severe plaque psoriasis. It has several product candidates targeting various indications such as MS, Parkinson's disease, CNS and neuromuscular disorders,, Alzheimer’s disease, and idiopathic pulmonary fibrosis and stroke. The company sells its products through direct sales force, marketing groups, and distributors in the Americas, Europe, Asia, and other territories. Biogen is headquartered in Cambridge, Massachusetts, the US.

Headquarters United States of America

Address 225 Binney St, Cambridge, Massachusetts, 02142-1031


Telephone 1 781 4642000

No of Employees 9,610

Industry Pharmaceuticals and Healthcare

Ticker Symbol & Exchange BIIB (NASD)

Revenue (2021) $11.0B -18.3% (2021 vs 2020)

EPS XXX

Net Income (2021) XXX -61.1% (2021 vs 2020)

Market Cap* $29.2B

Net Profit Margin (2021) XXX -52.4% (2021 vs 2020)

* As of and is in US$

Explore premium data & analytics

640+

Clinical Trials

Determine Biogen Inc go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

270+

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

250+

Catalyst Calendar

Proactively evaluate Biogen Inc’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.

160+

Pipeline Drugs

Identify which of Biogen Inc’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

150+

Lead Sheet

Understand when and why to target accounts of prospective leads, as well as who to reach out to, drawing on intelligence for Biogen Inc’s relevant decision makers and contact details.

30+

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

20+

Sales & Consensus Forecasts

Understand the current and future drug revenue for Biogen Inc and assess market opportunity for new entrants with patient population 8-year forecasts.

20+

Medical Clinical Trials

A database of clinical trials planned, currently ongoing, completed, suspended, withdrawn, and terminated in countries around the world.

16+

Marketed Drugs

Understand Biogen Inc’s commercialized product portfolio to stay one step ahead of the market.

11+

Medical Pipeline Products

A database of medical devices that are in the process to get approved for sale around the world. Devices that are in development, through to those in the approval process are included.

5

Medical Marketed Products

A database of medical devices currently for sale around the world. Devices that have been approved by a regulatory authority are included.

Subscribe to Company Analytics & gain access to premium industry data & analytics Subscribe to Company Analytics & gain access to premium industry data & analytics Start Here

Products and Services

Products Brands
Avonex: Alprolix
Multiple Sclerosis Avonex
Tysabri: Benepali
XXX XXX
XXX XXX
XXX XXX
Subscribe to Company Analytics for access to more products & services data Subscribe to Company Analytics for access to more products & services data Learn More

History

History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.

Year Event Description
2022 Regulatory Approval In May, the company, Eisai Co., Ltd completed the rolling submission to the U.S. Food and Drug Administration (FDA) of a Biologics License Application (BLA) under the accelerated approval pathway for the investigational anti-amyloid beta (Aβ) protofibril antibody lecanemab (BAN2401).
2022 Contracts/Agreements In May, the company and MedRhythms entered into a license agreement to develop and commercialize MR-004, an investigational prescription digital therapeutic for the treatment of gait deficits in multiple sclerosis.
2022 Plans/Strategy In May, the company announced its plans to help patients in the U.S on ADUHELM avoid any treatment interruptions following the final national coverage determination by Centers for Medicare & Medicaid Services (CMS).
Dive into past operations, including product releases, deals, acquisitions & more Dive into past operations, including product releases, deals, acquisitions & more Get Started
Image for loader

Competitor Comparison

Key Parameters Biogen Inc Johnson & Johnson Novartis AG Merck & Co Inc Bristol-Myers Squibb Co
Headquarters United States of America United States of America Switzerland United States of America United States of America
City Cambridge New Brunswick Basel Kenilworth New York
State/Province Massachusetts New Jersey - New Jersey New York
No. of Employees 9,610 141,700 110,000 68,000 32,200
Entity Type Public Public Public Public Public
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Find out more

Key Financial Charts

Net Income Growth

Image for loader
Operating Margin
Operating Margin
EPS (Earnings per Share)
EPS (Earnings per Share)
Debt to Equity Ratio
Debt to Equity Ratio
Return on Assets
Return on Assets
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Find out more
Executives
Name Position Board Since Age
Stelios Papadopoulos, Ph.D. Chairman Executive Board 2014 72
Michel Vounatsos Director; Chief Executive Officer Executive Board 2017 59
Michael McDonnell Executive Vice President; Chief Financial Officer Senior Management 2020 58
Robin C. Kramer Chief Accounting Officer; Senior Vice President Senior Management 2020 56
Susan H. Alexander Secretary; Chief Legal Officer; Executive Vice President Senior Management 2011 65
Non Dignissim Eros Proin vel Convallis 2022 XX
Non Dignissim Eros Proin vel Convallis 2022 XX
Non Dignissim Eros Proin vel Convallis 2022 XX
Gain more insight into company management & employee structure with Company Analytics Gain more insight into company management & employee structure with Company Analytics Subscribe

Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer